Browse by ▼

AstraZeneca plc (ADR)

  • Santarus Is a Real Gas!

    By Doug Lofton - May 21, 2013 | Tickers: AZN, AZN, NVS, SNTS

    Investing in the stock market can sometimes be a gut wrenching experience. However, for investors in Santarus (NASDAQ: SNTS), a pain in the gut can translate into big profits!

    Santarus is a bio-pharmaceutical company that produces and commercializes proprietary pharmaceutical products that address the needs of patients treated by gastroenterologists, endocrinologists, and other physician specialists.

    The following are three significant developments over the past year that collectively make Santarus a more »

  • Do Major Drug Manufacturers Have Room to Grow?

    By Chris Hodge - May 21, 2013 | Tickers: AZN, LLY, ZTS

    Major drug manufacturers are literally a market sector unto themselves. With valuations that frequently soar into the $50 billion level and beyond, these companies have already grown to incredible proportions. But can they grow further still, or is the best they can do to keep going along a steady path?

    Never underestimate a dark horse

    AstraZeneca (NYSE: AZN) is a Swedish and British company, which automatically puts its epicenter into more »

  • 2 Biopharmaceutical Companies Worth Buying

    By Mohsin Saeed - April 29, 2013 | Tickers: AZN, GALE, GILD

    The biotechnology industry had a good time last year and the market expects the trend to continue in 2013 as well. As the chart below shows, the AMEX biotechnology index has outperformed the S&P 500 index by a mile in the last one year. A major factor behind this stellar performance has been the large number of drug approvals by the FDA.

    I believe that the sector will continue more »

  • Bristol-Myers Squibb: Growing Bigger and Better

    By Shas Dey - April 19, 2013 | Tickers: AZN, BMY, MRK

    Bristol-Myers Squibb (NYSE: BMY) has been in the spotlight for its so-called “desired” acquisitions and its size issues, along with patent expiration news. Analysts have been debating the company's decision to expand and acquire companies in the face of declining revenue, wondering whether it makes sense to focus on product pipeline or growing bigger. I believe Bristol-Myers isn't looking at acquisitions apart from its product pipeline strategy. It more »

  • This Small Cap Pharmaceutical Stock Looks Interesting

    By Anh HOANG - April 17, 2013 | Tickers: AZN, BMY, MDCO

    Recently, Barron’s featured one pharmaceutical firm having potential catalysts that could drive its share price higher. That pharmaceutical firm is The Medicines (NASDAQ: MDCO). Since the middle of November 2012, The Medicines has advanced significantly, from around $20.40 per share to around $33 per share.

    The Medicines has four drugs, which might have FDA approval next year. Receiving FDA approval has always been a significant positive catalyst for more »

  • Time to Sell This Big Pharma Company

    By Mohsin Saeed - April 16, 2013 | Tickers: AZN, LLY, PFE

    The entire healthcare sector is going through a transitionary phase. A number of large drugs are losing their patent protection and this is creating serious headaches for large pharmaceutical companies. Major drugs like Seroquel IR and Lipitor are on their way out, creating headaches for their mother companies.

    Patent protection allows companies like Eli Lilly (NYSE: LLY) and Pfizer (NYSE: PFE) to charge premium prices for their products. So, once more »

  • Time to Sell This Big Pharma Company

    By Mohsin Saeed - April 16, 2013 | Tickers: AZN, LLY, PFE

    The entire healthcare sector is going through a transitionary phase. A number of large drugs are losing their patent protection and this is creating serious headaches for large pharmaceutical companies. Major drugs like Seroquel IR and Lipitor are on their way out, creating headaches for their mother companies.

    Patent protection allows companies like Eli Lilly (NYSE: LLY) and Pfizer (NYSE: PFE) to charge premium prices for their products. So, once more »

  • Bristol-Myers Squibb – Growing both bigger and better

    By Shas Dey - April 16, 2013 | Tickers: AZN, BMY, MRK

    Bristol-Myers Squibb (NYSE: BMY) has been in the spotlight for its acquisitions, so-called “desired” acquisitions and its size issues along with patent expiration news. Analysts have been debating BMY’s decisions to expand and acquire companies in the face of declining revenues, wondering whether it makes sense to focus on product pipeline at the moment or growing bigger. I believe BMY is not looking at acquisitions apart from its product more »

  • This Smallcap Pharmaceutical Stock is Opportunistic

    By Anh HOANG - April 14, 2013 | Tickers: AZN, BMY, MDCO

    Recently, Barron’s featured one pharmaceutical firm that could have potential catalyst to drive its share price higher. That pharmaceutical firm is The Medicines Co (NASDAQ: MDCO). Since the middle of November 2012, The Medicines has advanced significantly, from around $20.40 per share to around $33 per share. The Medicines have four drugs, which might have FDA approval next year. Receiving FDA approval has always been a significant positive more »

  • This Pharma Company Needs to Take Urgent Measures

    By Mohsin Saeed - April 8, 2013 | Tickers: AZN, PFE, TEVA

    A number of large pharmaceutical companies are currently undergoing a patent crisis. A large number of  star drugs are facing expiring patents, putting a lot of strain on FDA to increase their approval rate.

    AstraZeneca (NYSE: AZN) is one of the most affected companies when it comes to a diminishing patent portfolio. The company is facing a major generic threat to some of its key drugs. It's leading drugs more »

  • AstraZeneca: More Urgent Measures are Needed

    By Mohsin Saeed - April 4, 2013 | Tickers: AZN, PFE, TEVA

    A number of large-pharmaceutical companies are currently undergoing a patent crisis. As a large number of  star drugs are facing expiring patent which has put a lot of strain on FDA to increase their approval rate. AstraZeneca (NYSE: AZN) is one of the most affected companies when it comes to diminishing patent portfolio. The company is facing a major generic threat to some of its key drugs. It's leading more »

  • 3 Attractive Healthcare Dividend Stocks

    By Mohsin Saeed - March 29, 2013 | Tickers: ABBV, AZN, PETS

    The government has been trying to jump start our economy with low interest rates and other methods of quantitative easing. While these methods are imperative for improving the economy, they also reduce the attractiveness of interest-based instruments. This has made dividend stocks particularly attractive over the last couple of years.The following three healthcare companies offer pretty high dividends and fundamentals show that these dividends are sustainable.

    AbbVie (NYSE: ABBVmore »)

  • These European Pharmaceuticals Show Promise

    By Robert Ciura - March 27, 2013 | Tickers: AZN, NVS, SNY

    Companies in the health care sector provide essentials to both customers and investors: namely their products and their dividends. It’s safe to assume that people need to take their medicines, no matter the prevailing economic climate.

    When most investors think of big pharma, they’d likely come up with the usual suspects. While the U.S-based health care giants are well-known to most investors and worthy of investor consideration more »

  • AstraZeneca is Headed in the Right Direction

    By Mohsin Saeed - March 27, 2013 | Tickers: AMRN, AZN, SHPG

    In my last report on AstraZeneca (NYSE: AZN), I focused on the patent expiry of Seroquel IR and the resultant decline in company sales. According to recent news, the troubles of AstraZeneca are still not over and the company is cutting approximately 2,300 sales and admin jobs. This is part of a large plan put forward by the new CEO to jump start falling sales.

    Strategy shift

    The new more »

  • Time-Tested Pharmaceutical Stocks

    By Shas Dey - March 26, 2013 | Tickers: AMGN, AZN, GSK

    This article looks at three dividend paying biotechnology and drug stocks - two with above 4% dividend yields, AstraZeneca (NYSE: AZN) and GlaxoSmithKline (NYSE: GSK), and one that apart from being a dividend stock also has a significant growth potential, Amgen (NASDAQ: AMGN).

    Rationale for Dividend Investing in Today's Economy

    Taxing bank deposits was indeed insanity, and one wonders why it was even considered. Fortunately, the Cyprus madness did not more »

  • Celldex Is Still a Buy

    By Mohsin Saeed - March 26, 2013 | Tickers: AZN, CLDX, PFE

    There has been a significant rally in the share price of Celldex (NASDAQ: CLDX) recently. The stock is still showing positive momentum due to strong data on its drug trials. This positive data makes the company an attractive target for big pharmaceutical players like Pfizer (NYSE: PFE) and AstraZeneca (NYSE: AZN). I believe that the positive momentum will continue and that Celldex is still a buy despite recent rallies. 

    Celldex more »

  • What Big Companies Are Firing or Hiring?

    By Mark Morelli - March 23, 2013 | Tickers: AZN, KO, GOOG, BA

    Recently there has been a spat of information released regarding the employment picture among some big companies. Although the economy in general is improving and slowly creating jobs some large corporations have decided to scale back in a bid to change direction or refine operations. 

    The soft-drink maker Coca-Cola (NYSE: KO) just made an announcement that it was laying off 1% of its 75,000 strong U.S.-based workforce more »

  • Top # 10: International Companies (ADRs)

    By Rohit Gupta - March 18, 2013 | Tickers: BUD, AZN, GSK, NVS, NVO, SNY

    A list of Top 10 International companies, with ADRs (American Deposittory Receipts) listed in the US. While all large international brands – a synopsis of their unique competitive advantage and long term moat

    1. Anheuser-Busch (NYSE: BUD) : juggernaut in the global beer market with leadership position in four of the top five beer profit pools (United States, Canada, Brazil, and Mexico). Further, strength of ABI's focus brands (Budweiser, Stella Artois more »

  • Why Buffett Is Just Saying No to These Drug Majors

    By Cory Renauer - March 15, 2013 | Tickers: AZN, BMY, LLY

    Global pharmaceutical giants AstraZeneca (NYSE: AZN), Bristol-Myers Squibb Company (NYSE: BMY), and Eli Lilly & Company (NYSE: LLY) meet most of the growth and profitability criteria that Warren Buffett’s basic strategy is based on. So why isn’t he buying them?

    How they fit into Buffett’s strategy

    Below is a checklist for choosing companies that should offer steady returns and minimize losses during general economic downturns. Earnings per share more »

  • Are These Dividends Safe?

    By Rupert Hargreaves - March 13, 2013 | Tickers: AZN, PBI, TWO, WIN

    'Cliffs Natural Resources the biggest U.S. iron ore producer, fell the most in more than three years after cutting its quarterly dividend by 76 percent and announcing a share sale to repay debt.'

    'Cliffs reduced the payout to 15 cents a share, the Cleveland-based company said in a statement after the close of trading yesterday. That erases the increase made in March, when Cliffs raised the dividend to 62 more »

  • Page 1 of 5